Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiPlaCis in Advanced or Refractory Tumours
NCT01861496Phase 2Completed
- Sponsor
- Allarity Therapeutics
- Start
- Apr 2013
- Primary completion
- Oct 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liplacis in solid tumor, breast cancer, prostate cancer (PCa) and 1 more, sponsored by Allarity Therapeutics. Primary endpoint: Maximum Tolerated Dose and Recommended Dose at 1 year. Started Apr 2013; status: completed.
02
Drugs
liplacis
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)skin cancer
Beyond the preview
Go deeper on NCT01861496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861496.